|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: TAXOTERE
Summary for Tradename: TAXOTERE
|
| |||||||||
Clinical Trials for: TAXOTEREPharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer Status: Completed Condition: Advanced Solid Cancers Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors Status: Terminated Condition: Breast Cancer; Lung Cancer; Pulmonary Cancer; Non-Small-Cell Lung Carcinoma; Prostate Cancer; Prostatic Cancer; Gastric Cancer; Stomach Cancer Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer Status: Terminated Condition: Breast Cancer Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer Status: Recruiting Condition: Hormone Refractory Prostate Cancer Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer Status: Completed Condition: Lung Cancer Study of Usefulness of Genotyping to Predict Docetaxel Exposure and Adverse Events Status: Completed Condition: CYP3A Phenotyping; CYP3A5 and MDR1 Genotyping; Docetaxel Toxicity; Associations Between Genetic Data and Docetaxel Toxicity Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer Status: Completed Condition: Breast Cancer Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients Status: Recruiting Condition: Breast Cancer Randomized Study of Docetaxel +/- ZD6474 in Metastatic TCC Status: Active, not recruiting Condition: Transitional Cell Carcinoma; Urothelial Cancer Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC) Status: Not yet recruiting Condition: Non Small Cell Lung Cancer (NSCLC) Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | TAXOTERE | docetaxel | INJECTABLE; INJECTION | 020449 | Aug 2, 2010 | RX | Yes | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sanofi Aventis Us | TAXOTERE | docetaxel | INJECTABLE; INJECTION | 020449 | Aug 2, 2010 | RX | Yes | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sanofi Aventis Us | TAXOTERE | docetaxel | INJECTABLE; INJECTION | 020449 | Aug 2, 2010 | RX | Yes | 5,698,582*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sanofi Aventis Us | TAXOTERE | docetaxel | INJECTABLE; INJECTION | 020449 | Aug 2, 2010 | RX | Yes | 5,714,512*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: TAXOTERE
| Drugname | Dosage | Strength | RLD | Submissiondate |
| docetaxel | Injection | 40 mg/mL, 0.5 mL and 2 mL vials | Taxotere | 6/30/2009 |
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc